Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The… Source